<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00774189</url>
  </required_header>
  <id_info>
    <org_study_id>020/CLARI-250/03</org_study_id>
    <nct_id>NCT00774189</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Clarithromycin 250mg Tablets Under Fasting Conditions</brief_title>
  <official_title>An Open Label, Balanced, Randomised, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover Bioavailability Study on Clarithromycin Formulations, Comparing Clarithromycin 250 mg Tablets of Ranbaxy Laboratories With Biaxin 250 mg Tablets of Abbott Laboratories in Healthy, Adult, Human Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ranbaxy Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ranbaxy Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study was to compare the single-dose oral bioavailability of
      Clarithromycin 250 mg tablets of Ranbaxy Laboratories with Biaxin 250 mg tablets of Abbott
      Laboratories in healthy, adult, human subjects under fasting conditions
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an open label, balanced, and randomized, two-treatment, two-period, two-sequence,
      single-dose, crossover bioavailability study planned on 32 healthy, adult, human subjects
      under fasting conditions. 31 subjects completed both the periods of the study. Both periods
      were separated by a washout of twelve days The study was conducted on 32 healthy, adult,
      human subjects under fasting conditions. 31 subjects completed both the periods of the study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">November 2003</completion_date>
  <primary_completion_date type="Actual">August 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>clarithromycin 250 mg tablets of Ranbaxy Laboratories</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Biaxin 250 mg tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clarithromycin 250 mg tablets</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be in the age range of 18-45 years.

          2. Be neither overweight nor underweight for his/her height as per the Life Insurance
             Corporation of India height/weight chart for non-medical cases.

          3. Have voluntarily given written informed consent to participate in this study.

          4. Be of normal health as determined by medical history and physical

          5. Examination of the subjects performed .within 14 days prior to the commencement of the
             study.

          6. If female and:

        Of childbearing potential, is practicing an acceptable method of birth control for the
        duration of the study as judged by the investigator(s), such as condoms, foams, jellies,
        diaphragm, intrauterine device (IUD), or abstinence; or~ Is postmenopausal for at least 1
        year; or Is surgically sterile bilateral tubal ligation, bilateral oophorectomy, or
        hysterectomy)

        Exclusion Criteria:

          1. History of allergy to clarithromycin, erythromycin and related macrolides

          2. Any evidence of organ dysfunction or any clinically significant deviation from the
             normal, in physical or clinical determinations.

          3. Presence of disease markers of HIV 1 and 2, Hepatitis B and C viruses and syphilis
             infection.

          4. Female volunteers demonstrating a positive pregnancy screen.

          5. Female volunteers who are currently breastfeeding.

          6. Presence of values' which are clinically significantly different from normal reference
             ranges for haemoglobin, total white blood cells count, differential WBC count and
             platelet count

          7. Positive for urinary screen testing of drugs of abuse (opiates and cannabinoids

          8. Presence of values which are significantly different from normal.reference ranges (as
             defined in Appendix 5) for se- rum creatinine, blood urea nitrogen serum aspartate
             aminotransferase (AST), serum alanine aminotranferase (ALT), serum alkaline
             phosphatase, serum billrubin, plasma glucose and serum cholesterol

          9. Clinically abnormal chemical and microscopic examination of urine defined as presence
             of RBC, WBC (&gt;4/HPF), epithelial cells (&gt;4/HPF), glucose, (positive) and protein
             (positive).

         10. History of serious gastrointestinal, hepatic, renal, cardiovascular, pulmonary,
             neurological or hematological disease, diabetes or glaucoma.

         11. History of any psychiatric illness. which may impair the ability to provide written
             informed consent.

         12. Regular smokers who smoke more than 10 cigarettes daily or have difficulty abstaining
             from smoking for the duration of each study period.

         13. History of drug dependence or excessive alcohol intake on a habitual basis of more
             than 2 units of alcoholic beverages per day (1 'unit equivalent to half pint of beer
             or 1 glass of wine or 1 measure of spirit) or have difficulty in abstaining for the
             duration of each study period.

         14. Use of any enzyme modifying drugs within 30 days prior to Day I of this study

         15. Participation in any clinical trial within 12 weeks preceeding day 1 of study

         16. Subjects who, through completion of this study, would have donated and/or lost more
             than 350 mL of blood in past 3 months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ranbaxy Research Laboratories</name>
      <address>
        <city>Gurgaon</city>
        <state>Haryana</state>
        <zip>122001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.ranbaxy.com</url>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/Enforce.html</url>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
  </link>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/about.cfm</url>
  </link>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2008</study_first_submitted>
  <study_first_submitted_qc>October 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2008</study_first_posted>
  <last_update_submitted>October 16, 2008</last_update_submitted>
  <last_update_submitted_qc>October 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Tausif monif</name_title>
    <organization>Ranbaxy Research Labs</organization>
  </responsible_party>
  <keyword>Bioequivalence clarithromycin 250mg tablets fasting</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

